March 20, 2017

Importance of Recent Draft Guidances Is Getting Lost in the Transition of Administrations

In the days just before the presidential inauguration, the FDA issued two draft guidances on how companies communicate with payors for approved and investigational drugs and devices, and on what information is “consistent with labeling” and thus c...

You must be a subscriber to access this information. If you are a subscriber, please login. Not Yet A Subscriber? Click here to register for a free trial or contact Client Services at 800-677-3789 to activate your subscription.

Feedback Form
Leads to Insight